SEC filings and other documents

Settlement enables global phase III launch for onvansertib in RAS mutated colorectal cancer.

Phase 2 data support Phase 3 advancement for onvansertib in mCRC, with cash runway into Q3 2027.

Advancing a well-tolerated PLK1 inhibitor to global phase III for RAS-mutated colorectal cancer.

30 mg onvansertib plus FOLFIRI-BEV delivers 72% ORR and durable benefit in RAS-mutated mCRC.

Positive Phase 2 data, FDA alignment, and strong cash position support clinical momentum.

Onvansertib plus FOLFIRI+BEV achieved a 72% response rate and strong PFS in RAS mutated CRC.

Onvansertib shows 72% ORR and robust PFS in RAS-mutated mCRC, advancing to phase III trials.

Onvansertib plus FOLFIRI-Bev showed 72.2% ORR and extended PFS in RAS-mutated mCRC.

Onvansertib delivers high response rates and deep tumor regression in first-line RAS-mutated mCRC.

Strong Phase 2 results in RAS-mutated mCRC drive registrational plans and extend cash runway.

Promising clinical data and FDA alignment position onvansertib for first-line colorectal cancer.

Onvansertib demonstrated strong efficacy and safety in phase II, with phase III planned for next year.

Onvansertib delivers strong response rates and safety in first-line RAS-mutated mCRC, advancing to phase 3.

Onvansertib advances as a promising first-line therapy for RAS-mutated metastatic CRC.

Interim Phase 2 data showed a 19% ORR improvement for onvansertib in RAS-mutated mCRC.

Onvansertib shows strong efficacy and safety in first-line RAS-mutated MCRC, with major updates due in Q1 2026.

Onvansertib delivers rapid, deep responses in first-line colorectal cancer with minimal toxicity.

30 mg onvansertib plus standard of care achieved a 49% ORR and favorable safety in mCRC.

Phase 2 mCRC trial enrollment completed, positive mTNBC data, $71M cash runway into Q1 2027.

Phase 2 mCRC trial enrollment completed; cash runway extends into Q1 2027.